Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 1 study of oncolytic virus VV1 as monotherapy or in combination with avelumab in patients with relapsed refractory solid tumors.

Cancer research communications·2026
Same author

Racial disparities in pediatric cancer hospitalizations in the United States.

Cancer epidemiology·2026
Same author

Trabectedin decreases myeloid resistance to improve the efficacy of anti-PD1 immunotherapy and delay glioma malignant progression.

Molecular therapy. Oncology·2026
Same author

Erratum: Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 <i>in vitro</i> and <i>in vivo</i> in NB xenografts.

Molecular therapy. Oncology·2026
Same author

Cell-based potency assay for anti-CD3-anti-CD19 diabody.

Journal of immunological methods·2025
Same author

Development of VNX-101, an adeno-associated virus with less immunogenicity and efficient long-term expression of a CD19 T cell engager.

Molecular therapy. Methods & clinical development·2025

Related Experiment Video

Updated: Jun 6, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Ewing sarcoma: an eponym window to history.

Timothy P Cripe1

  • 1Division of Hematology/Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, ML7015, OH 45229, USA.

Sarcoma
|December 15, 2010
PubMed
Summary

James R. Ewing, a pathologist, first described Ewing sarcoma in 1921. His foundational work in oncology and cancer organizations significantly advanced cancer research and treatment.

Area of Science:

  • Oncology
  • Pathology
  • Cancer Research

Background:

  • Ewing sarcoma is a rare bone cancer named after James R. Ewing.
  • James R. Ewing was a pivotal figure in establishing oncology as a medical discipline.
  • His vision influenced the development of cancer research infrastructure and societies.

Purpose of the Study:

  • To highlight the profound and lasting contributions of James R. Ewing to oncology.
  • To acknowledge his role in the founding of major American cancer societies.
  • To emphasize the impact of his work on understanding and treating Ewing sarcoma.

Main Methods:

  • Historical review of James R. Ewing's contributions.
  • Analysis of his seminal textbook and founding of cancer organizations.

More Related Videos

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Related Experiment Videos

Last Updated: Jun 6, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

  • Examination of the impact on Ewing sarcoma research and patient care.

    • Main Results:

    • Ewing's work laid the groundwork for modern oncology.
    • He established key organizations that drive cancer research today.
    • These advancements have led to significant milestones in Ewing sarcoma understanding and treatment.

    Conclusions:

    • James R. Ewing's legacy extends far beyond the naming of Ewing sarcoma.
    • His foundational efforts continue to shape cancer research and patient care.
    • The infrastructure and societies he inspired are crucial for ongoing progress in oncology.